Wells Fargo & Company Verona Pharma PLC Call Options Transaction History
Wells Fargo & Company
- $407 Billion
- Q2 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding VRNA
# of Institutions
137Shares Held
66.7MCall Options Held
495KPut Options Held
486K-
Ra Capital Management, L.P. Boston, MA7.63MShares$223 Million1.66% of portfolio
-
Nea Management Company, LLC Timonium, MD5.58MShares$163 Million7.62% of portfolio
-
Deep Track Capital, LP Greenwich, CT4MShares$117 Million1.9% of portfolio
-
Vivo Capital, LLC Palo Alto, CA3.55MShares$104 Million7.58% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA3.31MShares$96.9 Million2.82% of portfolio
About Verona Pharma plc
- Ticker VRNA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 60,954,200
- Market Cap $1.78B
- Description
- Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodi...